Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Observational Studies of Salvage Treatment for Persistent Bacteremia: Beware of Survivor Treatment Selection Bias

Tattevin, Pierre, Uhel, Fabrice, Fily, Fabien · 2009 · Clinical Infectious Diseases

Abstract

To the Editor—Jang et al [1] recently published an observational study on the efficacy of linezolid with or without carbapenem in salvage treatment for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. They found that the MRSA-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P=.030) and concluded that linezolid, with or without carbapenem, produces better outcomes for patients with persistent MRSA bacteremia. Although they may be right, their manuscript failed to mention a significant limitation of these findings: the survivor treatment selection bias. Indeed, as the introduction of linezolid was treated as a time-invariant factor in their analysis, the authors did not take into account the fact that patients who received linezolid may be different from those who did not, simply by virtue of having survived until the date of treatment alteration [2]. In other words, longer survival may increase the patient's probability of receiving linezolid and, thus, lead to a survivor selection bias. Of note, in the study by Jang et al [1], there was a trend toward a longer duration of bacteremia in patients treated with a linezolid salvage regimen, with a mean (± standard deviation) of 26.4±38.8 days, compared with 11.8±3.9 days in patients continually treated with a vancomycin-based regimen [1]. Although not statistically significant, which comes of no surprise given the small samples size and the wide dispersion of values, this trend suggests that survivor treatment bias may account for most of the survival benefit attributed to linezolid by the authors. Indeed, if the differences observed were related to the efficacy of the linezolid salvage regimen, one would expect a shorter duration of bacteremia in patients treated with linezolid, compared with patients who continued to receive a vancomycin regimen. Treatment survivor bias is common in studies published in top medical journals [3] and frequently affects key factors and conclusions [4]. To adequately address this issue, the authors should consider linezolid introduction as a time-dependent covariate in their analysis. Potential conflicts of interest. All authors: no conflicts.

Overview

Integrity signals

Registry

Crossref · 10.1086/648500

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 4

Metadata

Authors
Tattevin, P., Uhel, F., & Fily, F.
Affiliations
Hôpital Pontchaillou (FR)
Corresponding author
Tattevin, Pierre
Venue
Clinical Infectious Diseases
Published
2009-12-15
Volume
49
Issue
12
Pages
1960-1961
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2147708573
Cited by
4
References
4
Citations by year
2019: 1 · 2015: 1 · 2014: 1
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Seoul
  • College of Medicine, Seoul National University
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
Keywords
persistent bacteremia, MRSA bacteremia, salvage therapy, linezolid, carbapenems, vancomycin, treatment selection bias, duration of bacteremia, time-varying covariates, observational study limitations
MeSH terms
Linezolid, Acetamides, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Staphylococcal Infections, Vancomycin, Bacteremia, Salvage Therapy, Oxazolidinones, Methicillin-Resistant Staphylococcus aureus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.